Cellceutix Received FDA Orphan Drug Designation For Kevetrin For The Treatment Of Pancreatic Cancer October 18, 2016 Cellceutix Corporation dermatology Kevetrin oncology Orphan Drug Designation +
FDA Grants Orphan Drug Designation To TapImmune Inc. TPIV 200 In The Treatment Of Ovarian Cancer September 29, 2016 cancer immunotherapeutics Inc. (TPIV) Office of Orphan Products Development OOPD Orphan Drug Designation peptide TapImmune TPIV 200 +